Hospira Reports Fourth-Quarter and Full-Year 2008 Results
-- Provides Sales and Earnings Projections for 2009 --
LAKE FOREST, Ill., February 17, 2009 /PRNewswire-FirstCall/ -- Hospira, Inc. , a leading global specialty pharmaceutical and medication delivery company, today reported results for the fourth quarter and full year ended Dec. 31, 2008. For the fourth quarter of 2008, net sales were $914 million, and adjusted* diluted earnings per share were $0.78. For the full year of 2008, net sales were $3.6 billion, and adjusted* diluted earnings per share were $2.53. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)
"Hospira delivered another positive year of performance in 2008, generating solid revenue and strong profit growth, further advancing key areas of our business and successfully completing the integration of the Mayne Pharma acquisition," said Christopher B. Begley, chairman and chief executive officer. "Looking forward, as a diversified healthcare company primarily serving the acute-care market, Hospira is well positioned in 2009. Hospira's underlying businesses remain solid, and we expect another year of growth guided by our focus on execution and operational optimization."
Fourth-Quarter 2008 Results
The following table highlights selected financial results for the fourth quarter of 2008 compared to the same period in 2007:
In $ millions, GAAP Adjusted*
except per Three Months Ended Three Months Ended
share amounts Dec. 31, Dec. 31,
---------------- % ---------------- %
2008 2007 Change 2008 2007 Change
------ ------ ------ ------ ------ ------
Net Sales $913.7 $946.1 (3.4)% n/a n/a n/a
Gross Profit $348.6 $338.6 3.0 % $376.4 $363.7 3.5 %
Income from
Operations $155.7 $114.0 36.6 % $188.2 $153.6 22.5 %
Diluted EPS $0.65 $0.47 38.3 % $0.78 $0.63 23.8 %
Statistics (as a % of Net Sales)
--------------------------------
Gross Profit 38.2 % 35.8 % 41.2 % 38.4 %
Operating Income 17.0 % 12.0 % 20.6 % 16.2 %
Results under U.S. Generally Accepted Accounting Principles (GAAP) include items as detailed in the schedules attached to this press release.
Net sales decreased 3.4 percent to $914 million in the fourth quarter of 2008, compared to $946 million in the fourth quarter of 2007. The decline was primarily driven by three factors: unfavorable foreign currency translation; unusually high U.S. wholesaler purchasing patterns for Specialty Injectable Pharmaceuticals in the fourth quarter of 2007; and decreased demand in Other Pharma from some contract manufacturing customers.
Medication Management Systems (MMS) reported solid sales growth based on continued demand for its newest general infusion system, Symbiq(R).
Adjusted* operating income increased 22.5 percent to $188 million in the fourth quarter of 2008, compared to $154 million in the fourth quarter of 2007. Contributing to the increase was favorable volume/mix, improved manufacturing efficiency and the impact of Selling, General & Administrative (SG&A) cost-containment measures.
Full-Year 2008 Results
The following table highlights selected financial results for the full year 2008 compared to the same period in 2007:
In $ millions, GAAP Adjusted*
except per Year Ended Year Ended
share amounts Dec. 31, Dec. 31,
---------------- % ---------------- %
2008 2007 Change 2008 2007 Change
------ ------ ------ ------ ------ ------
Net Sales $3,629.5 $3,436.2 5.6 % n/a n/a n/a
Gross Profit $1,322.0 $1,173.9 12.6 % $1,426.5 $1,325.1 7.7 %
Income from
Operations $517.8 $302.6 71.1 % $647.1 $579.6 11.6 %
Diluted EPS $1.99 $0.85 134.1 % $2.53 $2.19 15.5 %
Statistics (as a % of Net Sales)
--------------------------------
Gross Profit 36.4 % 34.2 % 39.3 % 38.6 %
Operating Income 14.3 % 8.8 % 17.8 % 16.9 %
Net sales increased 5.6 percent to $3.6 billion for the year ended Dec. 31, 2008, compared to $3.4 billion for the prior year. The increase was primarily a result of the impact of new group purchasing organization (GPO) awards; strong demand for the company's MMS product lines; and favorable foreign currency translation.
Adjusted* operating income increased 11.6 percent to $647 million for the full year of 2008, compared to $580 million for the full year of 2007. The increase is primarily a result of favorable volume/mix, improved manufacturing efficiencies and the impact of foreign exchange.
Cash Flow
Cash flow from operations for the full-year 2008 was $584 million, an increase compared to the $551 million generated in 2007.
Capital expenditures were $164 million for the full year, compared to $211 million in 2007. The decline is partly due to lower spending in 2008 than in 2007 related to the company's facilities optimization initiatives, as well as to capital-spending controls the company effected in the second half of 2008.
2009 Projections
Hospira expects net sales growth for full-year 2009 to be approximately 4 to 6 percent on a constant-currency basis. Including the impact of foreign exchange, the company expects net sales to be relatively flat. Adjusted* diluted earnings per share for 2009 are expected to be in the range of $2.62 to $2.72.
The reconciliation between the projected 2009 adjusted* diluted earnings per share and GAAP diluted earnings per share follows:
Diluted earnings per share -- adjusted* $2.62 - $2.72
--------------
Estimated charges related to planned facilities
optimization initiatives (mid-point of an estimated
range of $0.10 to $0.12 per diluted share for 2009) ($0.11)
Estimated $53 million for the amortization of
intangibles related to the Mayne Pharma acquisition ($0.23)
--------------
Diluted earnings per share -- GAAP $2.28 - $2.38
==============
The company projects that cash flow from operations in 2009 will be in the $565 million to $615 million range. Depreciation and amortization is expected to be between $210 million and $220 million. Capital expenditures are projected to be between $155 million and $175 million.
"Our 2009 guidance aligns with our core strategies to improve margins and cash flow and invest for growth," said Begley. "We have a robust global generic drug pipeline and attractive growth opportunities in generic injectables. With our expanded GPO contracts, we expect to attract additional customers to our broad portfolio of products. We also expect continued momentum with MMS as we advance our technologically enhanced offerings. Through our streamlined, focused management and optimization initiatives, we are well positioned to advance our growth opportunities and drive sustainable long-term growth."
*Use of Non-GAAP Financial Measures
Non-GAAP financial measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.
Webcast
Hospira will hold a conference call for investors and media at 8 a.m. Central time on Tuesday, Feb. 17, 2009. A live webcast of the conference call will be available at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup for receiving the webcast. A replay will be available on the Hospira Web site for 30 days following the call.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
Hospira, Inc.
Condensed Consolidated Statements of Income
(Unaudited)
(dollars and shares in millions, except for per share amounts)
Three Months Ended Years Ended
December 31, December 31,
--------------- % ------------------ %
2008 2007 Change 2008 2007 Change
------ ------ ------- -------- -------- -------
Net sales $913.7 $946.1 (3.4)% $3,629.5 $3,436.2 5.6 %
Cost of products
sold 565.1 607.5 (7.0)% 2,307.5 2,262.3 2.0 %
------ ------ -------- --------
Gross Profit 348.6 338.6 3.0 % 1,322.0 1,173.9 12.6 %
Research and
development 53.5 53.7 (0.4)% 213.6 201.2 6.2 %
Acquired
in-process
research and
development - 3.2 (100.0)% 0.5 88.0 (99.4)%
Selling,
general and
administrative 139.4 167.7 (16.9)% 590.1 582.1 1.4 %
------ ------ -------- --------
Income From
Operations 155.7 114.0 36.6 % 517.8 302.6 71.1 %
Interest expense 29.0 32.0 (9.4)% 116.2 134.5 (13.6)%
Other expense
(income), net 0.6 (7.7)(107.8)% (5.9) (19.7) (70.1)%
------ ------ -------- --------
Income Before
Income Taxes 126.1 89.7 40.6 % 407.5 187.8 117.0 %
Income tax expense 21.5 13.6 58.1 % 86.6 51.0 69.8 %
------ ------ -------- --------
Net Income $104.6 $76.1 37.5 % $320.9 $136.8 134.6 %
====== ====== ======== ========
Earnings Per
Common Share:
Basic $0.66 $0.48 37.5 % $2.02 $0.87 132.2 %
====== ====== ======== ========
Diluted $0.65 $0.47 38.3 % $1.99 $0.85 134.1 %
====== ====== ======== ========
Weighted Average
Common Shares
Outstanding:
Basic 159.5 157.8 1.1 % 159.2 156.9 1.5 %
====== ====== ======== ========
Diluted 160.9 160.3 0.4 % 161.3 160.2 0.7 %
====== ====== ======== ========
Hospira, Inc.
Reconciliation of Condensed Consolidated Statements of Income
(Unaudited)
(dollars and shares in millions, except per share amounts)
Three Months Ended December 31,
-------------------------------------------------------
2008 2007
-------------------------- --------------------------
GAAP Adjustments Adjusted GAAP Adjustments Adjusted
------ ------ ------ ------ ------ ------
Net sales $913.7 $ - $913.7 $946.1 $ - $946.1
Cost of
products sold 565.1 (27.8)A 537.3 607.5 (25.1)E 582.4
------ ------ ------ ------ ------ ------
Gross Profit 348.6 27.8 376.4 338.6 25.1 363.7
Research and
development 53.5 (0.5)B 53.0 53.7 (0.3)C 53.4
Acquired
in-process
research and
development - - - 3.2 (3.2)G -
Selling,
general and
administrative 139.4 (4.2)C 135.2 167.7 (11.0)C 156.7
------ ------ ------ ------ ------ ------
Income From
Operations 155.7 32.5 188.2 114.0 39.6 153.6
Interest expense 29.0 - 29.0 32.0 1.4 F 33.4
Other expense
(income), net 0.6 - 0.6 (7.7) - (7.7)
------ ------ ------ ------ ------ ------
Income Before
Income Taxes 126.1 32.5 158.6 89.7 38.2 127.9
Income tax
expense 21.5 10.8 D 32.3 13.6 14.0 D 27.6
------ ------ ------ ------ ------ ------
Net Income $104.6 $21.7 $126.3 $76.1 $24.2 $100.3
====== ====== ====== ====== ====== ======
Earnings Per
Common Share:
Basic $0.66 $0.13 $0.79 $0.48 $0.16 $0.64
====== ====== ====== ====== ====== ======
Diluted $0.65 $0.13 $0.78 $0.47 $0.16 $0.63
====== ====== ====== ====== ====== ======
Weighted Average
Common Shares
Outstanding:
Basic 159.5 159.5 159.5 157.8 157.8 157.8
====== ====== ====== ====== ====== ======
Diluted 160.9 160.9 160.9 160.3 160.3 160.3
====== ====== ====== ====== ====== ======
Statistics
(as a % of
Net Sales,
except for
income tax rate)
-----------------
Gross Profit 38.2% 41.2% 35.8% 38.4%
R&D 5.9% 5.8% 5.7% 5.6%
SG&A 15.3% 14.8% 17.7% 16.6%
Income From
Operations 17.0% 20.6% 12.0% 16.2%
Income Before
Income Taxes 13.8% 17.4% 9.5% 13.5%
Net Income 11.4% 13.8% 8.0% 10.6%
Income Tax Rate 17.1% 20.4% 15.2% 21.5%
% Change vs. Prior Year
-----------------------
GAAP Adjusted
------- --------
Net sales (3.4)% (3.4)%
Cost of products sold (7.0)% (7.7)%
Gross Profit 3.0 % 3.5 %
Research and development (0.4)% (0.7)%
Acquired in-process research and
development (100.0)% nm
Selling, general and administrative (16.9)% (13.7)%
Income From Operations 36.6 % 22.5 %
Interest expense (9.4)% (13.2)%
Other expense (income), net (107.8)% (107.8)%
Income Before Income Taxes 40.6 % 24.0 %
Income tax expense 58.1 % 17.0 %
Net Income 37.5 % 25.9 %
Earnings Per Common Share:
Basic 37.5 % 23.4 %
Diluted 38.3 % 23.8 %
Weighted Average Common Shares Outstanding:
Basic 1.1 % 1.1 %
Diluted 0.4 % 0.4 %
A -- Includes intangible assets amortization of $16.0 related to the Mayne
Pharma acquisition; charges of $9.0 related to the planned closures
of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan
Hill, CA facilities as part of Hospira's facilities optimization
initiatives; and Mayne Pharma integration and other acquisition-
related charges of $2.8.
B -- Facilities optimization initiatives.
C -- Mayne Pharma integration and other acquisition-related charges.
D -- Reflects the tax effect of the above adjustments.
E -- Includes intangible assets amortization of $12.6 related to the Mayne
Pharma acquisition; charges of $4.1 related to the planned closures
of the Donegal, Ireland; Ashland, OH; Montreal, Canada; and North
Chicago, IL facilities as part of Hospira's facilities optimization
initiatives; Mayne Pharma integration charges of $0.9; and intangible
asset impairment of $7.5 related to a non-strategic device product.
F -- Other acquisition-related (charge) refund: refund of bridge loan fees
incurred as a result of the Mayne Pharma acquisition expensed upon
refinancing of loan during the first quarter of 2007.
G -- Acquired in-process research and development.
nm = Percent change is not meaningful.
Hospira, Inc.
Reconciliation of Condensed Consolidated Statements of Income
(Unaudited)
(dollars and shares in millions, except per share amounts)
Years Ended December 31,
---------------------------------------------------------
2008 2007
---------------------------- ---------------------------
GAAP Adjustments Adjusted GAAP Adjustments Adjusted
-------- ----- ------- ------- ------ -------
Net sales $3,629.5 $ - $3,629.5 $3,436.2 $ - $3,436.2
Cost of
products sold 2,307.5 (104.5)A 2,203.0 2,262.3 (151.2)F 2,111.1
-------- ----- ------- ------- ------ -------
Gross Profit 1,322.0 104.5 1,426.5 1,173.9 151.2 1,325.1
Research and
development 213.6 (3.3)B 210.3 201.2 (1.6)D 199.6
Acquired
in-process
research and
development 0.5 (0.5)C - 88.0 (88.0)C -
Selling,
general and
administrative 590.1 (21.0)D 569.1 582.1 (36.2)D 545.9
-------- ----- ------- ------- ------ -------
Income From
Operations 517.8 129.3 647.1 302.6 277.0 579.6
Interest expense 116.2 - 116.2 134.5 (0.8)G 133.7
Other expense
(income), net (5.9) - (5.9) (19.7) (5.7)H (25.4)
-------- ----- ------- ------- ------ -------
Income Before
Income Taxes 407.5 129.3 536.8 187.8 283.5 471.3
Income tax
expense 86.6 42.1 E 128.7 51.0 69.3 E 120.3
-------- ----- ------- ------- ------ -------
Net Income $320.9 $87.2 $408.1 $136.8 $214.2 $351.0
======== ===== ======= ======= ====== =======
Earnings Per
Common Share:
Basic $2.02 $0.54 $2.56 $0.87 $1.37 $2.24
======== ===== ======= ======= ====== =======
Diluted $1.99 $0.54 $2.53 $0.85 $1.34 $2.19
======== ===== ======= ======= ====== =======
Weighted Average
Common Shares
Outstanding:
Basic 159.2 159.2 159.2 156.9 156.9 156.9
======== ===== ======= ======= ====== =======
Diluted 161.3 161.3 161.3 160.2 160.2 160.2
======== ===== ======= ======= ====== =======
Statistics
(as a % of
Net Sales,
except for
income tax rate)
-----------------
Gross Profit 36.4% 39.3% 34.2% 38.6%
R&D 5.9% 5.8% 5.9% 5.8%
SG&A 16.3% 15.7% 16.9% 15.9%
Income From
Operations 14.3% 17.8% 8.8% 16.9%
Income Before
Income Taxes 11.2% 14.8% 5.5% 13.7%
Net Income 8.8% 11.2% 4.0% 10.2%
Income Tax Rate 21.3% 24.0% 27.2% 25.5%
% Change vs. Prior Year
-----------------------
GAAP Adjusted
------- --------
Net sales 5.6 % 5.6 %
Cost of products sold 2.0 % 4.4 %
Gross Profit 12.6 % 7.7 %
Research and development 6.2 % 5.4 %
Acquired in-process research and
development (99.4)% nm
Selling, general and administrative 1.4 % 4.2 %
Income From Operations 71.1 % 11.6 %
Interest expense (13.6)% (13.1)%
Other expense (income), net (70.1)% (76.8)%
Income Before Income Taxes 117.0 % 13.9 %
Income tax expense 69.8 % 7.0 %
Net Income 134.6 % 16.3 %
Earnings Per Common Share:
Basic 132.2 % 14.3 %
Diluted 134.1 % 15.5 %
Weighted Average Common Shares Outstanding:
Basic 1.5 % 1.5 %
Diluted 0.7 % 0.7 %
A -- Includes intangible assets amortization of $62.8 related to the Mayne
Pharma acquisition; charges of $35.6 related to the planned closures
of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan
Hill, CA facilities as part of Hospira's facilities optimization
initiatives; a gain on the sale of the Montreal, Canada manufacturing
plant ($2.5); and Mayne Pharma integration and other acquisition-
related charges of $8.6.
B -- Includes Mayne Pharma integration and other acquisition-related
charges of $1.0 and facilities optimization initiatives of $2.3.
C -- Acquired in-process research and development.
D -- Mayne Pharma integration and other acquisition-related charges.
E -- Reflects the tax effect of the above adjustments.
F -- Includes inventory step-up charge of $53.1 and intangible assets
amortization of $47.6 related to the Mayne Pharma acquisition;
charges of $37.6 related to the planned closures of the Donegal,
Ireland; Ashland, OH; Montreal, Canada; and North Chicago, IL
facilities as part of Hospira's facilities optimization initiatives;
a reduction of the obligation associated with the sale of the Salt
Lake City, UT manufacturing plant to ICU Medical ($1.6); Mayne Pharma
integration charges of $7.0; and intangible asset impairment of
$7.5 related to a non-strategic device product.
G -- Other acquisition-related charge: $2.2 of bridge loan fees incurred
as a result of the Mayne Pharma acquisition expensed upon refinancing
of loan during the first quarter of 2007 net of a refund of $1.4
received in the fourth quarter of 2007.
H -- Other acquisition-related charge: foreign exchange losses related to
the Mayne Pharma acquisition.
nm = Percent change is not meaningful.
Hospira, Inc.
Reconciliation of Diluted Earnings Per Share
(Unaudited)
Three Months Ended Years Ended
December 31, December 31,
------------------- --------------------
2008 2007 2008 2007
------ ------ ------ ------
Diluted Earnings Per
Share - GAAP $0.65 $0.47 $1.99 $0.85
Adjustments:
Mayne Pharma acquisition
related:
Acquired in-process
research and
development - - - 0.53
Inventory step-up
charge - - - 0.23
Integration and
other acquisition-
related charges 0.02 0.04 0.12 0.21
Intangible assets
amortization 0.06 0.06 0.27 0.20
Charges related to
facilities optimization
initiatives 0.04 0.02 0.15 0.14
Intangible asset
impairment related to
a non-strategic device
product - 0.03 - 0.03
Acquired in-process
research and
development related to
product acquisition - 0.01 - 0.01
Integration and other
acquisition-related
charges 0.01 - 0.01 -
Gain on the sale of the
Montreal, Canada
manufacturing plant - - (0.01) -
Reduction of obligation
associated with the
sale of the Salt Lake
City, UT manufacturing
plant - - - (0.01)
------ ------ ------ ------
Subtotal of Adjustments 0.13 0.16 0.54 1.34
Diluted Earnings Per
Share - Adjusted $0.78 $0.63 $2.53 $2.19
====== ====== ====== ======
Hospira, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(dollars in millions)
December 31, December 31,
Assets 2008 2007
-------- --------
Current Assets:
Cash and cash equivalents $483.8 $241.1
Trade receivables, less allowances of
$6.7 in 2008 and $14.1 in 2007 583.4 559.0
Inventories 830.5 766.6
Deferred income taxes 172.2 176.7
Prepaid expenses 35.7 23.8
Other receivables 43.7 73.8
-------- --------
Total Current Assets 2,149.3 1,841.0
-------- --------
Property and equipment, net 1,192.1 1,276.9
Intangible assets, net 404.4 554.0
Goodwill 1,167.4 1,240.9
Deferred income taxes 70.1 79.4
Investments 37.6 23.7
Other assets 53.2 68.8
-------- --------
Total Assets $5,074.1 $5,084.7
======== ========
Liabilities and Shareholders' Equity
Current Liabilities:
Short-term borrowings $338.3 $58.5
Trade accounts payable 231.5 190.3
Salaries, wages and commissions 144.7 143.6
Deferred income taxes 1.5 8.4
Other accrued liabilities 331.5 393.5
-------- --------
Total Current Liabilities 1,047.5 794.3
-------- --------
Long-term debt 1,834.0 2,184.4
Deferred income taxes 25.2 50.7
Post-retirement obligations and other
long-term liabilities 391.0 310.1
Commitments and Contingencies
-------- --------
Total Shareholders' Equity 1,776.4 1,745.2
-------- --------
Total Liabilities and Shareholders' Equity $5,074.1 $5,084.7
======== ========
Hospira, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(dollars in millions)
Years Ended December 31,
------------------------
2008 2007
-------- --------
Cash Flow From Operating Activities:
Net income $320.9 $136.8
Adjustments to reconcile net income to net
cash from operating activities --
Depreciation 183.2 183.0
Amortization of intangibles 68.7 52.1
Write-off of acquired in-process research
and development 0.5 88.0
Step-up value of acquired inventories sold - 53.1
Stock-based compensation expense 42.0 39.4
Impairment of long-lived assets - 7.5
Net gains on sales of assets (3.0) (5.0)
Changes in assets and liabilities --
Trade receivables (55.4) (47.6)
Inventories (117.9) 34.4
Prepaid expenses and other assets 12.9 17.7
Trade accounts payable 49.5 11.5
Other liabilities 52.9 (40.3)
Other, net 29.8 20.5
-------- --------
Net Cash Provided by Operating Activities 584.1 551.1
-------- --------
Cash Flow From Investing Activities:
Capital expenditures (including instruments
placed with or leased to customers) (164.3) (210.5)
Acquisitions, net of cash acquired, including
payments for deferred consideration (26.1) (1,980.5)
Purchases of intangibles and other investments (50.8) (5.5)
(Purchases) Sales of marketable securities (24.5) 10.4
Settlements of foreign currency contracts - (55.7)
Proceeds from dispositions of product rights - 13.8
Proceeds from disposal of facilities 0.8 -
-------- --------
Net Cash Used in Investing Activities (264.9) (2,228.0)
-------- --------
Cash Flow From Financing Activities:
Issuance of long-term debt, net of fees paid - 3,336.2
Repayment of long-term debt (95.2) (1,825.2)
Other borrowings, net 6.3 (6.2)
Excess tax benefit from stock-based
compensation arrangements 1.0 2.3
Proceeds from stock options exercised 27.8 73.1
-------- --------
Net Cash (Used in) Provided by Financing
Activities (60.1) 1,580.2
-------- --------
Effect of exchange rate changes on cash
and cash equivalents (16.4) 15.8
-------- --------
Net change in cash and cash equivalents 242.7 (80.9)
Cash and cash equivalents at beginning of year 241.1 322.0
-------- --------
Cash and cash equivalents at end of year $483.8 $241.1
======== ========
Supplemental Cash Flow Information:
Cash paid during the year --
Interest $120.8 $127.4
Income taxes, net of refunds $14.9 $72.4
Hospira, Inc.
Net Sales by Product Line
(Unaudited)
(dollars in millions)
Three Months Ended December 31,
----------------------------------------
% Change % Change
at Actual at Constant
2008 2007 Rates Rates
-------- -------- ------- -------
Americas --
Pharmaceuticals
Specialty Injectables $347.2 $349.7 (0.7)% 1.3 %
Other Pharma 147.6 155.6 (5.1)% (2.4)%
-------- --------
494.8 505.3 (2.1)% 0.1 %
Devices
Medication Management Systems 140.6 129.1 8.9 % 12.4 %
Other Devices 85.8 94.1 (8.8)% (6.6)%
-------- --------
226.4 223.2 1.4 % 4.3 %
Total Americas 721.2 728.5 (1.0)% 1.4 %
Europe, Middle East & Africa --
Pharmaceuticals
Specialty Injectables 63.2 71.1 (11.1)% 0.3 %
Other Pharma 31.9 51.0 (37.5)% (25.8)%
-------- --------
95.1 122.1 (22.1)% (10.6)%
Devices
Medication Management Systems 16.7 16.6 0.6 % 11.6 %
Other Devices 16.0 16.9 (5.3)% 5.6 %
-------- --------
32.7 33.5 (2.4)% 8.5 %
Total Europe, Middle East &
Africa 127.8 155.6 (17.9)% (6.5)%
Asia Pacific --
Pharmaceuticals
Specialty Injectables 50.1 47.3 5.9 % 27.7 %
Other Pharma 3.1 3.3 (6.1)% 21.2 %
-------- --------
53.2 50.6 5.1 % 27.2 %
Devices
Medication Management Systems 4.4 4.4 0.0 % 11.9 %
Other Devices 7.1 7.0 1.4 % 5.7 %
-------- --------
11.5 11.4 0.9 % 8.1 %
Total Asia Pacific 64.7 62.0 4.4 % 23.8 %
-------- --------
Net Sales $913.7 $946.1 (3.4)% 1.6 %
======== ========
Years Ended December 31,
----------------------------------------
% Change % Change
at Actual at Constant
2008 2007 Rates Rates
-------- -------- ------- -------
Americas --
Pharmaceuticals
Specialty Injectables $1,328.9 $1,240.9 7.1 % 7.1 %
Other Pharma 522.0 549.2 (5.0)% (4.7)%
-------- --------
1,850.9 1,790.1 3.4 % 3.5 %
Devices
Medication Management Systems 558.9 501.3 11.5 % 11.4 %
Other Devices 368.5 367.5 0.3 % 0.1 %
-------- --------
927.4 868.8 6.7 % 6.6 %
Total Americas 2,778.3 2,658.9 4.5 % 4.5 %
Europe, Middle East & Africa --
Pharmaceuticals
Specialty Injectables 287.4 255.4 12.5 % 8.0 %
Other Pharma 152.1 162.3 (6.3)% (8.1)%
-------- --------
439.5 417.7 5.2 % 1.8 %
Devices
Medication Management Systems 75.9 66.4 14.3 % 7.6 %
Other Devices 68.4 68.0 0.6 % (4.6)%
-------- --------
144.3 134.4 7.4 % 1.4 %
Total Europe, Middle East &
Africa 583.8 552.1 5.7 % 1.6 %
Asia Pacific --
Pharmaceuticals
Specialty Injectables 205.4 168.9 21.6 % 19.6 %
Other Pharma 15.2 14.1 7.8 % 4.8 %
-------- --------
220.6 183.0 20.5 % 18.4 %
Devices
Medication Management Systems 19.9 16.7 19.2 % 15.5 %
Other Devices 26.9 25.5 5.5 % (0.7)%
-------- --------
46.8 42.2 10.9 % 5.7 %
Total Asia Pacific 267.4 225.2 18.7 % 16.1 %
-------- --------
Net Sales $3,629.5 $3,436.2 5.6 % 4.8 %
======== ========
Notes:
Specialty Injectables include generic injectables and proprietary
specialty injectables. Other Pharmaceuticals include large volume IV
solutions, nutritionals and contract manufacturing services (including
former "Sales to Abbott"). Medication Management Systems include infusion
pumps, related software, services and administration sets. Other Devices
include gravity administration sets, critical care products, and other
device products.
Net sales for the years ended December 31, 2008 and 2007, include twelve
and eleven months, respectively, of Mayne Pharma net sales.
Hospira, Inc.
Segment Information
(Unaudited)
(dollars in millions)
Three Months Ended December 31,
----------------------------------------------------------
Net Sales Income from Operations
----------------- ------------------
% %
2008 2007 Change 2008 2007 Change
------ ------ ------ ------ ------ ------
Americas $721.2 $728.5 (1.0)% $172.0 A $142.4 A 20.8 %
Europe,
Middle East
& Africa 127.8 155.6 (17.9)% 2.1 B (0.4)B 625.0 %
Asia Pacific 64.7 62.0 4.4 % 9.4 C 4.9 C 91.8 %
------ ------ ------ ------
Total
reportable
segments $913.7 $946.1 (3.4)% 183.5 146.9 24.9 %
====== ======
Corporate
functions (19.0)D (25.1)D (24.3)%
Stock-based
compensation (8.8) (7.8) 12.8 %
------ ------
Income from
operations 155.7 114.0 36.6 %
Interest
expense and
other income,
net (29.6)E (24.3)E 21.8 %
------ ------
Income before
income taxes $126.1 $89.7 40.6 %
====== ======
Included in the reported Income before
income taxes above, are the following charges:
A -- Americas
Mayne Pharma acquisition related:
Acquired in-process research and
development $ - $ -
Inventories step-up charge - -
Integration and other acquisition-
related charges 1.5 1.8
Intangible assets amortization 4.2 2.0
Charges related to facilities
optimization initiatives 9.5 3.5
Intangible asset impairment related
to a non-strategic device product - 7.5
Integration and other acquisition-
related charges 0.1 -
Acquired in-process research and
development - -
Gain on the sale of the Montreal,
Canada manufacturing plant - -
Reduction of obligation associated with
the sale of the Salt Lake City, UT
manufacturing plant - -
------ ------
Total Americas 15.3 14.8
B -- Europe, Middle East & Africa
Mayne Pharma acquisition related:
Acquired in-process research and
development - -
Inventories step-up charge - -
Integration and other acquisition-
related charges 0.5 4.3
Intangible assets amortization 8.1 5.8
Charges related to facilities
optimization initiatives - 0.6
Acquired in-process research and
development - 3.2
------ ------
Total Europe, Middle East & Africa 8.6 13.9
C -- Asia Pacific
Mayne Pharma acquisition related:
Inventories step-up charge - -
Integration and other acquisition-
related charges 1.6 1.7
Intangible assets amortization 3.7 4.8
Integration and other acquisition-
related charges 0.2 -
------ ------
Total Asia Pacific 5.5 6.5
D -- Corporate functions
Integration and other acquisition-
related charges 3.1 4.4
------ ------
Total Corporate functions 3.1 4.4
E -- Interest expense and other
income, net
Integration and other acquisition-
related charges, net of refund - (1.4)
------ ------
Total Interest expense and other
income, net - (1.4)
------ ------
Total $32.5 $38.2
====== ======
Hospira, Inc.
Segment Information
(Unaudited)
(dollars in millions)
Years Ended December 31,
----------------------------------------------------------
Net Sales Income from Operations
------------------- ------------------
% %
2008 2007 Change 2008 2007 Change
-------- -------- ------ ------ ------ ------
Americas $2,778.3 $2,658.9 4.5 % $598.0 A $445.3 A 34.3 %
Europe,
Middle East
& Africa 583.8 552.1 5.7 % 12.8 B (16.6)B 177.1 %
Asia Pacific 267.4 225.2 18.7 % 23.0 C (4.2)C 647.6 %
-------- -------- ------ ------
Total
reportable
segments $3,629.5 $3,436.2 5.6 % 633.8 424.5 49.3 %
======== ========
Corporate
functions (74.0)D (82.5)D (10.3)%
Stock-based
compensation (42.0) (39.4) 6.6 %
------ ------
Income from
operations 517.8 302.6 71.1 %
Interest
expense and
other income,
net (110.3)E (114.8)E (3.9)%
------ ------
Income before
income taxes $407.5 $187.8 117.0 %
====== ======
Included in the reported Income before
income taxes above, are the following charges:
A -- Americas
Mayne Pharma acquisition related:
Acquired in-process research and
development $ - $66.2
Inventories step-up charge - 10.0
Integration and other acquisition-
related charges 3.6 14.8
Intangible assets amortization 19.2 9.4
Charges related to facilities
optimization initiatives 37.9 35.7
Intangible asset impairment related
to a non-strategic device product - 7.5
Integration and other acquisition-
related charges 0.1 -
Acquired in-process research and
development 0.5 -
Gain on the sale of the Montreal,
Canada manufacturing plant (2.5) -
Reduction of obligation associated with
the sale of the Salt Lake City, UT
manufacturing plant - (1.6)
------ ------
Total Americas 58.8 142.0
B -- Europe, Middle East & Africa
Mayne Pharma acquisition related:
Acquired in-process research and
development - 18.6
Inventories step-up charge - 18.0
Integration and other acquisition-
related charges 10.6 6.4
Intangible assets amortization 25.8 21.5
Charges related to facilities
optimization initiatives - 1.9
Acquired in-process research
and development - 3.2
------ ------
Total Europe, Middle East & Africa 36.4 69.6
C -- Asia Pacific
Mayne Pharma acquisition related:
Inventories step-up charge - 25.1
Integration and other acquisition-
related charges 7.1 3.6
Intangible assets amortization 17.8 16.7
Integration and other acquisition-
related charges 1.4 0.6
------ ------
Total Asia Pacific 26.3 46.0
D -- Corporate functions
Integration and other acquisition-
related charges 7.8 19.4
------ ------
Total Corporate functions 7.8 19.4
E -- Interest expense and other
income, net
Integration and other acquisition-
related charges, net of refund - 6.5
------ ------
Total Interest expense and other
income, net - 6.5
------ ------
Total $129.3 $283.5
====== ======
CONTACT: Media, Stacey Eisen, +1-224-212-2276, or Tareta Adams,+1-224-212-2535, or Financial Community, Karen King, +1-224-212-2711, allof Hospira, Inc.
Web site: http://www.hospira.com/
Ticker Symbol: (NYSE:HSP)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2009
